TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01005394

Intervention type: DEVICE
Intervention: Navigated TMS examination
Description: diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
Study: NCT03601416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation of mesenchymal stem cell
Description: Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Transplantation of Mesenchymal Stem Cell
Description: Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
Study: NCT01324583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT00120445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air
Description: 0.3 ml of filtered air

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: expansile gas
Description: 0.3 ml of perfluoropropane gas
Study: NCT04303169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vibostolimab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev
Description: Administered via IT injection at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab + Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days
Study: NCT03623321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: • Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
Study: NCT04002440

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: AMIA with SHARESOURCE Connectivity Platform
Description: The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HomeChoice PRO
Description: Usual care
Study: NCT03819179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Serum
Description: This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Serum with Biulin
Description: This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, PreBIULIN FOS (GOVA).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Serum with Bonicell
Description: This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, Bonicel (Ganaden).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Serum with Berenew Complex
Description: This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, BeRenew CLR Complex (CLR).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Serum with Ecoskin
Description: This is a commercially available over-the-counter product. Ingredients: Caprylic/Capric Triglyceride, Dimer Dilinoleyl Dimer Dilionoleatem, Silica, Citronellyl Methylcrotonate, Tocopheryl Acetate, Xymenynic Acid, Alpha-glucan Oligosaccharide, Fragrance, Slareolide, Polymnia sonshifolia root juice, Helianthus annuus (sunflower) seed oil, Maltodextrin, Tocopherol, Beta-sitosterol, Lactobacillus, Squalene.
Study: NCT00005022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT04303169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: Administered via oral capsules at a specified dose on specified days
Study: NCT02344927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Clinically Assisted Hydration arm
Description: Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
Study: NCT00005022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT02344927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinically Assisted Hydration arm
Description: Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
Study: NCT00005022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT00141193

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Study: NCT01908387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral azacitidine
Description: 100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
Study: NCT02091960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country
Study: NCT00005022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00263276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 2.5 mg, Once daily, 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 5 mg, Once daily, 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 20 mg, Once daily, 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 50 mg, Once daily, 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, Oral, \>/= 1500 mg, Once daily, 12 weeks.
Study: NCT03455959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy/BAL
Description: Participants may receive 3 inhalations (90 ug ea) of albuterol to minimize bronchoconstriction. Medication includes midazolam by intravenous injection, and fentanyl by intravenous injection as judged necessary. 2% lidocaine is delivered via atomizer spray to the oral pharynx for local anesthesia. 1% lidocaine is delivered through the bronchoscope to the vocal cords and lung segments for local anesthesia. The bronchoscope is then passed through the vocal cords into the trachea. Throughout the procedure, all participants will have continuous blood pressure, heart rate, and oxygen saturation monitoring. Participants will be instructed to relate any discomfort or problems through a series of standardized hand signals. Once in the lung, aliquots of sterile saline are instilled into two subsegments of the right middle lobe (preferred and if not possible then the right upper lobe) and withdrawn into a trap by gentle suction.
Study: NCT04595591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg/kg/min
Description: titration dosing speeds of propofol at 2mg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg/kg/min
Description: titration dosing speeds of propofol at 1mg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg/kg/min
Description: titration dosing speeds of propofol at 0.5mg/kg/min
Study: NCT00942721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT for PPD
Description: A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
Study: NCT00691704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide Induction
Description: Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Maintenance Therapy
Description: Subjects who achieve \>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \> stable disease (SD) from maintenance (per discussion with physician):~* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~* Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~* Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle.
Study: NCT00555893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight \<=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)
Study: NCT01275677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00555893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: \<=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
Study: NCT02557464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An eye tracking experiment
Description: Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An eye tracking experiment
Description: Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A neuropsychological evaluation
Description: Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A neuropsychological evaluation
Description: Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
Study: NCT03283748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensors
Description: Wearable sensors will be given to the participants to be worn and movement data will be collected
Study: NCT03619330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: In the liraglutide group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
Study: NCT03390257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3NT flexible endoscope
Description: The nasal anatomy will be accessed and viewed with the device during Balloon Sinus Dilation
Study: NCT02465684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unicondylar knee arthroplasty
Study: NCT03455959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway Brushing
Description: After completion of the BALs, endobronchial brushing of the airways will be performed using the airway brushings with a Conmed Harrell™ 4 mm unsheathed cytology brush. Upon completing the brushing the investigators remove the bronchoscope with the brush in place to avoid shearing off isolated cells. The brush will be gently glided back and forth on the airway epithelium 10 times in 2 different locations within the same airway. The brush is then placed in media and flicked to remove the cells. A second brush will then be introduced into an adjacent airway of the same lobe and gently glided back and forth on the airway epithelium 10 times in 2 different locations as was done with the first brush. The second brush will also be placed in media and flicked to remove the cells. There is some airway bleeding caused by the procedure, and participants are made aware that they may cough up small amounts of blood for 24-48 hours following the procedure.
Study: NCT04082455

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiotherapy
Description: carbon ion radiotherapy
Study: NCT01425775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D 25(OH)D
Description: 2000IU/day for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
Study: NCT00005022

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03668366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
Study: NCT00005022

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03337750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-PE Therapy
Description: Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
Study: NCT01985698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted resection.
Description: Robotic-assisted abdominoperineal resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic resection
Description: Laparoscopic abdominoperineal resection
Study: NCT03617874

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PC4PrEP- Intervention Clinics
Description: PC4PrEP is a comprehensive, multi-level, structural and sustainable intervention designed to address barriers at system, provider, and user levels to increase PrEP uptake.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Clinics
Description: The standard of care model is the model approved by the health system for their health care clinics.
Study: NCT01930617

Intervention type: PROCEDURE
Intervention: Burr hole surgery with various drainage techniques
Description: Surgical technique~1. Continuous irrigation and drainage~2. Passive subdural drain~3. Active subgaleal drain

Intervention type: PROCEDURE
Intervention: Burr hole surgery with various drainage techniques
Description: Surgical technique~1. Continuous irrigation and drainage~2. Passive subdural drain~3. Active subgaleal drain

Intervention type: PROCEDURE
Intervention: Burr hole surgery with various drainage techniques
Description: Surgical technique~1. Continuous irrigation and drainage~2. Passive subdural drain~3. Active subgaleal drain
Study: NCT01275677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT05447039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Sodium Tablets
Description: intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days
Study: NCT00625742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Resistance Training
Description: Resistance training sessions twice weekly using Thera-bands.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
Study: NCT02781155

Intervention type: OTHER
Group type: OTHER
Intervention: Moxibustion
Description: Participants are taught to self administer moxibustion to acupuncture point Zusanli St-36 daily throughout the course of their chemotherapy
Study: NCT02062905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study: NCT04610203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25 g Nutralys Pea Protein
Description: To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose +25g Nutralys S85 Plus

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50 g Nutralys S85 Plus.
Description: To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose+50 g Nutralys S85 Plus .
Study: NCT04610203

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 50 g Glucose
Description: To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose
Study: NCT00625742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 20 mg by mouth (PO) Daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven
Description: 90 calories of Juven, twice a day.
Study: NCT02948946

Intervention type: PROCEDURE
Intervention: NETest
Description: 5 mL of blood will be drawn from participants for testing.

Intervention type: PROCEDURE
Intervention: NETest
Description: 5 mL of blood will be drawn from participants for testing.
Study: NCT03090217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Physiotherapy
Description: 1) daily pelvic floor muscle training (PFMT).
Study: NCT00625742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate \>110 beats/min) or resting energy expenditure (REE) \> 110% of predicted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 1200mg/day in three divided doses.
Study: NCT01764425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P7435
Description: It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
Study: NCT03090217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care (SC)
Description: 1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
Study: NCT01764425

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P7435
Description: It is oral DGATI inhibitor with potential in dyslipidemia and T2DM